'Promotes Low Blood Pressure' Is Already a Drug Claim

why is hypertension named inside fda's own definition of disease?

Hypertension is not a symptom cluster or a risk factor in FDA's rulebook — it is named as a disease outright, in the same clause that names diabetes. The 2000 final rule implementing 21 CFR 101.93 states plainly that "elevated blood pressure (hypertension) and elevated cholesterol (hypercholesterolemia) are diseases themselves," not markers of some other condition waiting to happen.

That single sentence forecloses almost every soft framing a copywriter reaches for.

We counted: FDA's own list of claims meeting the significant scientific agreement standard runs to exactly twelve, and only one touches blood pressure at all — sodium linked to hypertension under 21 CFR 101.74. It's a food-labeling claim with its own wording restrictions, and the blood pressure claim FDA allows comes at a real cost to how the product gets sold, not a template you paste onto a capsule label.

why does the soft verb 'promotes' fail where marketers expect it to pass?

'Promotes' fails because FDA pre-empted the exact word, not just the concept. The same 1994 preamble adds, without hedging, that "a claim that a product promotes low blood pressure would be considered a disease claim" — not implies, not risks being read as, simply would be.

Structure/function copy ordinarily leans on verbs like supports, promotes and maintains precisely because they describe a body function rather than a disease outcome. That's the whole architecture behind structure/function claims, and it's why the verb usually carries more weight than the noun.

Blood pressure is the one condition where the noun overrides the verb every time.

did fda accept the argument that blood pressure is only a risk factor?

No — FDA rejected the risk-factor defense in the same rule that would have supported it. The preamble treats hypertension as the disease itself, not a precursor to one, which closes off the common argument that a product merely supports a risk marker rather than treating a diagnosed condition.

Marketers often treat cholesterol and blood pressure copy as interchangeable, since FDA named both 'diseases themselves' in the identical sentence of the identical rule — that assumption is wrong. Cholesterol got a food-claim escape hatch blood pressure never did: 21 CFR 101.75 lets a qualifying food claim reduced coronary heart disease risk through saturated fat and cholesterol reduction, and the cholesterol claims FDA actually authorized run wider than most operators assume. Blood pressure's only authorized route stops at sodium.

what did hekma center get cited for without promising a cure?

Hekma Center's letter (FDA reference 637652, dated June 2, 2023) shows FDA doesn't need a cure promise to act. Describing a disease's signs or its mechanism is already enough under the second criterion of 21 CFR 101.93(g)(2), which reaches claims about a product's effect on characteristic signs or symptoms stated in either scientific or lay terminology — no cure verb required.

We could not verify the exact phrases FDA quoted from Hekma Center's product pages against the letter's primary text in this pass — the case number and date are confirmed, the copy itself is not. Reading the full letter on FDA's warning-letter database would settle it.

why did 'normalizes blood pressure' not protect meta labs?

'Normalizes' failed Meta Labs (FDA reference 725130, dated May 15, 2026) for the same reason 'promotes' fails everyone else: the preamble's language covers the direction of the claim, not the word chosen to express it. Whether a product claims to raise, lower or normalize blood pressure, it is still claiming an effect on a named disease.

Compare that to blood sugar, where 'helps maintain levels already within the normal range' is common, defensible structure/function language for a condition FDA hasn't named as a disease outright — a distinction covered in the blood sugar niche's market and claim ceiling. Copy your blood-sugar page's normalizing language straight onto a blood-pressure product, and you inherit blood pressure's ceiling, not blood sugar's.

why did publishing their own hypertension study hurt calroy?

Calroy's own hypertension study (FDA reference 636311, dated November 14, 2022) hurt the company on two fronts at once. Citing a disease-referencing publication inside labeling is itself one of the ten triggers under 21 CFR 101.93(g)(2) — the rule treats a cited study about a disease as evidence of intended disease treatment when the labeling, taken as a whole, implies treatment or prevention.

We checked FTC's separate bar next. Its Health Products Compliance Guidance states that "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing," and a single company-run observational study doesn't clear that floor even when FDA's disease-claim question is set aside entirely.

what wording is left when half the audience is already medicated?

What survives is narrow, and it has nothing to do with the word 'pressure.' A product can describe support for healthy circulation, healthy blood flow already within a normal range for people who are not diagnosed, or general cardiovascular wellness — language that stays inside structure and function rather than reaching for the diagnosed state. What it cannot do is speak to the roughly half of adult hypertension patients already on medication, because 21 CFR 101.93(g)(2) separately treats a product as making a disease claim if it substitutes for a therapy, augments a drug's action, or manages a therapy's side effects — three more of the ten triggers, and none of them requires the word 'cure.'

The DSHEA disclaimer does not fix any of this.

That's the misconception that keeps recurring: the boilerplate line — "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease" — accompanies a lawful structure/function claim. It doesn't convert an unlawful one, per 21 CFR 101.93 at Cornell's Legal Information Institute, and no warning letter in this set was closed out simply by adding it after the fact.

how does meta's personal-attributes rule hit 'is your pressure high?' copy?

Meta's rule works exactly the way its own example pair shows: a line like 'Depression counseling' is compliant, and a line like 'Depression getting you down? Get help now.' is not, because the Privacy Violations and Personal Attributes policy bars ads that assert or imply a viewer's own medical condition. Swap the disease and the same test applies to blood pressure creative.

'Is your pressure high?' addresses the viewer's own body directly and fails the same way the depression example does. 'Blood pressure support' names a category without asserting anything about the person looking at the ad, which is the entire difference the rule turns on.

Category reference survives; direct diagnosis never does.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, The Calm Claims FDA Listed as Acceptable, The Dementia Claim That Prints Its Own Rebuttal, Absentmindedness Is Allowed. Memory Loss Is Not., Prevagen: Seven Years of Litigation Over a Chart, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.